Stock Movers Hims & Hers Gains, Abbott Slides, Allbirds Sinks
Apr 16, 2026
Carmen Reineke, a Bloomberg reporter who covers market and company moves, breaks down big stock swings. She outlines Hims & Hers rally after peptide rule-talk. She covers Abbott trimming guidance tied to an acquisition. She recounts Allbirds’ wild AI pivot surge and sharp reversal.
AI Snips
Chapters
Transcript
Episode notes
Hims & Hers Rally From Peptide Regulation Shift
- Hims & Hers stock jumped after RFK Jr. said the FDA seeks to remove 12 peptides from Category 2 restrictions.
- Carmen Reineke noted the company signaled it would sell peptides once regulations loosen, extending a two-day rally.
Abbott Cuts Guidance After Exact Sciences Deal
- Abbott shares fell after cutting full-year adjusted EPS guidance tied to its Exact Sciences acquisition.
- Carmen Reineke said the deal aimed to bolster diagnostics, which have struggled since COVID testing waned.
Allbirds Volatility After AI Pivot Announcement
- Allbirds surged then crashed after announcing a pivot toward AI infrastructure, producing extreme volatility.
- Carmen Reineke described Wednesday's 600% up day as followed by a roughly 28% decline the next session.